CancerDrs

Ovarian Cancer clinical trials in Florida

87 actively recruiting ovarian cancer trials at 52 sites across Florida.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Florida:
  • AdventHealth Altamonte — Altamonte Springs, Florida
  • Mount Sinai Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • Florida Cancer Specialists - Bradenton Cancer Center — Bradenton, Florida
  • Morton Plant Hospital — Clearwater, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a poly…

Sponsor: NRG Oncology
NCT ID: NCT06580314
Sites in Florida:
  • Holy Cross Hospital — Fort Lauderdale, Florida
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
  • Orlando Health Cancer Institute - Lake Mary — Lake Mary, Florida
  • Health Central — Ocoee, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

This is a clinical study that has three parts. It is testing a potential new medicine called Sofetabart Mipitecan (Sofe-M) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A enrolls participants with p…

Sponsor: Eli Lilly and Company
NCT ID: NCT07213804
Sites in Florida:
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Florida Cancer Specialist- South — Fort Myers, Florida
  • Baptist MD Anderson Cancer Center — Jacksonville, Florida
  • University of Miami Hospital and Clinics, Sylvester Cancer Center — Miami, Florida
  • Mount Sinai Braman Comprehensive Cancer Center — Miami Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07214779
Sites in Florida:
  • Mount Sinai Medical Center Comprehensive Cancer Center — Miami Beach, Florida
  • Brcr Global — Miramar, Florida
  • Sarasota Memorial Health Care System — Sarasota, Florida
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.

Sponsor: Daiichi Sankyo
NCT ID: NCT06161025
Sites in Florida:
  • Sylvester Comprehensive Cancer Center at Lennar — Coral Gables, Florida
  • Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Florida Cancer Specialists — Lake Mary, Florida
  • Sylvester Cancer Center — Miami, Florida
  • Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary perito…

Sponsor: AstraZeneca
NCT ID: NCT07218809
Sites in Florida:
  • Research Site — Fort Lauderdale, Florida
  • Research Site — Gainesville, Florida
  • Research Site — Jupiter, Florida
  • Research Site — Miami, Florida
  • Research Site — Weston, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.

Sponsor: Verastem, Inc.
NCT ID: NCT06072781
Sites in Florida:
  • Florida Cancer Specialists - South — Fort Myers, Florida
  • Mount Sinai — Miami Beach, Florida
  • AdventHealth — Orlando, Florida
  • Moffitt Cancer Center — Tampa, Florida
  • Florida Cancer Specialists Research East — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer get…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06824467
Sites in Florida:
  • Mount Sinai Braman Comprehensive Cancer Center ( Site 0078) — Miami Beach, Florida
  • Sarasota Memorial Hospital ( Site 0075) — Sarasota, Florida
  • Florida Cancer Specialists East ( Site 7000) — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

This clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expr…

Sponsor: Daiichi Sankyo
NCT ID: NCT06819007
Sites in Florida:
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • Jupiter Medical Center — Jupiter, Florida
  • Mount Sinai Medical Center — Miami Beach, Florida
  • AdventHealth Cancer Institute — Orlando, Florida
  • Woman's Care FL — St. Petersburg, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard ca…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07318558
Sites in Florida:
  • Mount Sinai Cancer Center ( Site 0029) — Miami Beach, Florida
  • Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085) — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant…

Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04575935
Sites in Florida:
  • University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
  • Cleveland Clinic Foundation - Florida — Weston, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

Sponsor: Imunon
NCT ID: NCT06915025
Sites in Florida:
  • Advent Health — Orlando, Florida
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

This study will evaluate the efficacy, safety and tolerability of Torvutatug samrotecan (torvu-sam) in combination with bevacizumab compared with bevacizumab monotherapy as first line maintenance treatment in patients with Homologous Recom…

Sponsor: AstraZeneca
NCT ID: NCT07851025
Sites in Florida:
  • Research Site — Tampa, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Florida:
  • UM Sylvester Comprehensive Cancer Center at Aventura — Aventura, Florida
  • UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
  • Broward Health Medical Center — Fort Lauderdale, Florida
  • UF Health Cancer Institute - Gainesville — Gainesville, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with fo…

Sponsor: AbbVie
NCT ID: NCT06890338
Sites in Florida:
  • Jupiter Medical Center /ID# 276616 — Jupiter, Florida
  • Mount Sinai Medical Center /ID# 274868 — Miami Beach, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conduct…

Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
NCT ID: NCT05128825
Sites in Florida:
  • Site 0241 - Florida Cancer Specialist - North — Altamonte Springs, Florida
  • Site 0173 - Mount Sinai Medical Center — Miami Beach, Florida
  • Site 0308 - Advent Health — Orlando, Florida
  • Site 0239 - Florida Cancer Specialists - East — Wellington, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone an…

Sponsor: Artios Pharma Ltd
NCT ID: NCT04657068
Sites in Florida:
  • Florida Cancer Specialists — Fort Myers, Florida
  • Mayo Clinic (Florida) — Jacksonville, Florida
  • Cancer Specialists of North Florida — Jacksonville, Florida
  • Florida Cancer Specialists — Orlando, Florida
  • Florida Cancer Specialists — Sarasota, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Sponsor: Incyte Corporation
NCT ID: NCT07023627
Sites in Florida:
  • Florida Cancer Specialists & Research Institute — Fort Myers, Florida
  • Sylvester Comprehensive Cancer Center — Miami, Florida
  • Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida
  • Florida Cancer Specialists & Research Institute — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Florida:
  • University of Miami - Sylvester Comprehensive Cancer Center — Miami, Florida
  • Advent Health — Orlando, Florida
  • Florida Cancer Specialists South — Port Charlotte, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary ce…

Sponsor: Fore Biotherapeutics
NCT ID: NCT05503797
Sites in Florida:
  • University of Miami Hospital and Clinics — Miami, Florida
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine …

Sponsor: AbbVie
NCT ID: NCT07059845
Sites in Florida:
  • University of Florida College of Medicine /ID# 278348 — Gainesville, Florida
  • Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623 — Orlando, Florida
  • Florida Cancer Specialists - North /ID# 278626 — St. Petersburg, Florida
  • Florida Cancer Specialists - East /ID# 278605 — West Palm Beach, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Florida:
  • Research Site 118 — Celebration, Florida
  • Research Site 127 — Margate, Florida
  • Research Site 137 — Orlando, Florida
  • Research Site 101 — Plantation, Florida
  • Research Site 109 — Tamarac, Florida
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …

Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in Florida:
  • University of Miami — Coral Gables, Florida
  • Moffitt Cancer Center and Research Institute — Tampa, Florida
View on ClinicalTrials.gov →

Showing 25 of 87 trials with sites in Florida. See all ovarian cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12